Vistagen Therapeutics (VTGN) Competitors $2.61 -0.06 (-2.25%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends VTGN vs. PTI, MACK, KOD, PRQR, IMMP, RZLT, ITOS, VYGR, CCCC, and QUREShould you be buying Vistagen Therapeutics stock or one of its competitors? The main competitors of Vistagen Therapeutics include Proteostasis Therapeutics (PTI), Merrimack Pharmaceuticals (MACK), Kodiak Sciences (KOD), ProQR Therapeutics (PRQR), Immutep (IMMP), Rezolute (RZLT), iTeos Therapeutics (ITOS), Voyager Therapeutics (VYGR), C4 Therapeutics (CCCC), and uniQure (QURE). These companies are all part of the "medical" sector. Vistagen Therapeutics vs. Proteostasis Therapeutics Merrimack Pharmaceuticals Kodiak Sciences ProQR Therapeutics Immutep Rezolute iTeos Therapeutics Voyager Therapeutics C4 Therapeutics uniQure Proteostasis Therapeutics (NASDAQ:PTI) and Vistagen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, valuation, community ranking, dividends, institutional ownership, profitability, analyst recommendations, earnings and risk. Which has stronger valuation & earnings, PTI or VTGN? Vistagen Therapeutics has lower revenue, but higher earnings than Proteostasis Therapeutics. Vistagen Therapeutics is trading at a lower price-to-earnings ratio than Proteostasis Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProteostasis Therapeutics$5M0.00-$59.13M-$1.16N/AVistagen Therapeutics$1.06M68.55-$29.36M-$1.24-2.10 Is PTI or VTGN more profitable? Proteostasis Therapeutics has a net margin of 0.00% compared to Vistagen Therapeutics' net margin of -4,521.71%. Vistagen Therapeutics' return on equity of -36.35% beat Proteostasis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Proteostasis TherapeuticsN/A -75.39% -55.04% Vistagen Therapeutics -4,521.71%-36.35%-33.62% Does the media prefer PTI or VTGN? In the previous week, Vistagen Therapeutics had 1 more articles in the media than Proteostasis Therapeutics. MarketBeat recorded 1 mentions for Vistagen Therapeutics and 0 mentions for Proteostasis Therapeutics. Vistagen Therapeutics' average media sentiment score of 1.75 beat Proteostasis Therapeutics' score of 0.00 indicating that Vistagen Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Proteostasis Therapeutics Neutral Vistagen Therapeutics Very Positive Which has more risk and volatility, PTI or VTGN? Proteostasis Therapeutics has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, Vistagen Therapeutics has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Does the MarketBeat Community believe in PTI or VTGN? Proteostasis Therapeutics received 35 more outperform votes than Vistagen Therapeutics when rated by MarketBeat users. However, 72.31% of users gave Vistagen Therapeutics an outperform vote while only 59.03% of users gave Proteostasis Therapeutics an outperform vote. CompanyUnderperformOutperformProteostasis TherapeuticsOutperform Votes31759.03% Underperform Votes22040.97% Vistagen TherapeuticsOutperform Votes28272.31% Underperform Votes10827.69% Do institutionals and insiders hold more shares of PTI or VTGN? 16.6% of Proteostasis Therapeutics shares are owned by institutional investors. Comparatively, 78.4% of Vistagen Therapeutics shares are owned by institutional investors. 4.8% of Proteostasis Therapeutics shares are owned by company insiders. Comparatively, 1.3% of Vistagen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts rate PTI or VTGN? Vistagen Therapeutics has a consensus target price of $15.00, suggesting a potential upside of 474.71%. Given Vistagen Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Vistagen Therapeutics is more favorable than Proteostasis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Proteostasis Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Vistagen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 SummaryVistagen Therapeutics beats Proteostasis Therapeutics on 11 of the 18 factors compared between the two stocks. Ad Crypto 101 MediaTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Get Vistagen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTGN vs. The Competition Export to ExcelMetricVistagen TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$74.34M$6.48B$5.05B$8.87BDividend YieldN/A8.12%4.97%4.06%P/E Ratio-2.105.5697.3414.18Price / Sales68.55348.141,218.4289.42Price / CashN/A22.1533.5132.79Price / Book0.787.885.805.12Net Income-$29.36M$153.61M$119.07M$225.99M7 Day Performance-4.40%-2.00%-1.83%-1.32%1 Month Performance-13.00%-7.47%-3.64%0.60%1 Year Performance-20.18%31.80%31.62%26.23% Vistagen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTGNVistagen Therapeutics3.774 of 5 stars$2.61-2.2%$15.00+474.7%-25.4%$74.34M$1.06M-2.1040Positive NewsPTIProteostasis TherapeuticsN/AN/AN/AN/A$37.57M$5M-0.6244Gap UpMACKMerrimack PharmaceuticalsN/A$15.13flatN/AN/A$223.77MN/A1.09426Analyst ForecastKODKodiak Sciences2.9773 of 5 stars$5.79+2.7%$3.50-39.6%+138.3%$296.80MN/A0.0090PRQRProQR Therapeutics2.0484 of 5 stars$3.67+1.9%$7.13+94.1%+143.0%$294.05M$7.05M0.00180IMMPImmutep1.3099 of 5 stars$1.96-3.0%$8.50+333.7%+4.8%$293.82M$5.14M0.002,021RZLTRezolute4.1532 of 5 stars$5.01+1.2%$24.13+381.5%+568.0%$290.28MN/A-3.9440ITOSiTeos Therapeutics3.4955 of 5 stars$7.85-0.6%$31.50+301.3%-23.0%$288.62M$12.60M0.0090VYGRVoyager Therapeutics4.6613 of 5 stars$5.36+1.7%$17.00+217.2%-21.6%$287.88M$250.01M7.55100Analyst UpgradeAnalyst RevisionGap UpCCCCC4 Therapeutics2.6434 of 5 stars$4.05-2.4%$10.00+146.9%+139.6%$285.89M$33.67M-2.38150Analyst ForecastQUREuniQure3.0892 of 5 stars$5.70-2.1%$17.00+198.2%-18.2%$283.68M$15.84M0.00500Negative News Related Companies and Tools Related Companies PTI Alternatives MACK Alternatives KOD Alternatives PRQR Alternatives IMMP Alternatives RZLT Alternatives ITOS Alternatives VYGR Alternatives CCCC Alternatives QURE Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VTGN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vistagen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vistagen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
